Novartis Balances Regulatory Wins with Upcoming Pipeline and Earnings Tests

Novartis enters a critical week with two new regulatory approvals, three high-stakes pipeline readouts looming, and mixed earnings history testing its premium valuation.

The Swiss pharmaceutical giant enters a defining week where a string of recent regulatory victories collides with an earnings report and the looming verdict on three high-stakes clinical trials. Investors are watching whether the confluence of catalysts can sustain the premium valuation the stock commands relative to its peers.

Approvals Broaden the Base

Within days, Novartis secured two significant regulatory milestones. The US Food and Drug Administration granted full, regular approval for Fabhalta (iptacopan) in IgA nephropathy, a chronic kidney disease, upgrading the previous accelerated authorization. The decision rested on phase III data showing a slower decline in estimated glomerular filtration rate compared with placebo. Separately, the European Union approved the gene therapy Itvisma for spinal muscular atrophy. Both decisions expand Novartis’s commercial offering beyond its established core products, adding evidence that regulators are willing to back its pipeline.

Pipeline Readouts Take Center Stage in the Second Half

With the approval news absorbed, investor attention pivots to three late-stage readouts scheduled for the second half of 2026. Reuters reports that Pelacarsen in cardiovascular disease, Remibrutinib in multiple sclerosis, and Del-desiran in a genetic disorder are considered pivotal for the company’s long-term valuation. Analysts estimate the combined peak sales potential of these three assets at more than $10 billion, a sum that, if realised, would justify Novartis trading at roughly 16 times earnings.

Goldman Sachs believes at least two of the three studies must deliver positive results for the stock’s premium to its sector to hold. UBS has set a benchmark for Pelacarsen: a relative risk reduction of around twelve percent. A markedly lower figure would likely trigger a negative market response.

Earnings History Shows a Mixed Record

Novartis reports second-quarter results on July 21, 2026. The consensus estimate stands at $2.16 in earnings per share, down from the $2.47 earned in the same quarter last year. The first quarter of 2026 saw a miss: EPS of $1.99 versus the $2.07 analysts had forecast. Looking further back, the fourth quarter of 2025 slightly beat expectations ($2.03 versus $2.00), while the third quarter of 2025 missed ($2.25 versus $2.29). The second quarter of 2025 delivered a clear beat at $2.47 versus $2.38. The mixed pattern means Tuesday’s report will be parsed closely for signs of whether margins have recovered from the first-quarter shortfall.

Institutional Caution and Stock Price Consolidation

Institutional signals offer a nuanced picture. Dimensional Fund Advisors trimmed its Novartis holding by 4.9% in the first quarter, reducing the position to 8.11 million shares valued at $1.24 billion. The consensus analyst rating on the stock is “Hold” with a price target of $141.20.

The shares have been consolidating near their highs. Ahead of the earnings release, the stock traded at 135.14 euros but slipped 0.34% on the day of the report to 134.60 euros, leaving it about six-and-a-half percent below the 52-week high of 144.30 euros set in late February. Year-to-date, the stock has gained 13.89%. Looking further ahead, long-term forecasts based on the recent approvals and pipeline progress project sales of $65.6 billion and net income of $18.1 billion by 2029, with a fair value estimate of CHF 123.55 per share. Whether the next few weeks validate that optimism now depends on how the earnings number and the subsequent study readouts align with expectations.